152 related articles for article (PubMed ID: 19944746)
1. The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats.
Yang SY; Hong CJ; Huang YH; Tsai SJ
Neurosci Lett; 2010 Jan; 469(1):127-30. PubMed ID: 19944746
[TBL] [Abstract][Full Text] [Related]
2. Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA/2 mice.
Kopec K; Flood DG; Gasior M; McKenna BA; Zuvich E; Schreiber J; Salvino JM; Durkin JT; Ator MA; Marino MJ
Biochem Pharmacol; 2010 Nov; 80(9):1407-17. PubMed ID: 20637735
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action.
Javitt DC; Duncan L; Balla A; Sershen H
Mol Psychiatry; 2005 Mar; 10(3):275-87. PubMed ID: 15278098
[TBL] [Abstract][Full Text] [Related]
4. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
Kawaura K; Koike H; Kinoshita K; Kambe D; Kaku A; Karasawa J; Chaki S; Hikichi H
Behav Brain Res; 2015 Feb; 278():186-92. PubMed ID: 25300471
[TBL] [Abstract][Full Text] [Related]
5. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.
Karasawa J; Hashimoto K; Chaki S
Behav Brain Res; 2008 Jan; 186(1):78-83. PubMed ID: 17854919
[TBL] [Abstract][Full Text] [Related]
6. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex.
Konradsson A; Marcus MM; Hertel P; Svensson TH; Jardemark KE
Synapse; 2006 Aug; 60(2):102-8. PubMed ID: 16715496
[TBL] [Abstract][Full Text] [Related]
8. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Tsai G; Lane HY; Yang P; Chong MY; Lange N
Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
[TBL] [Abstract][Full Text] [Related]
9. The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior.
Kinney GG; Sur C; Burno M; Mallorga PJ; Williams JB; Figueroa DJ; Wittmann M; Lemaire W; Conn PJ
J Neurosci; 2003 Aug; 23(20):7586-91. PubMed ID: 12930797
[TBL] [Abstract][Full Text] [Related]
10. Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-D-aspartate (NMDA) glutamatergic receptor blockade.
Levin ED; Petro A; Caldwell DP
Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):581-6. PubMed ID: 15866361
[TBL] [Abstract][Full Text] [Related]
11. Disruption of prepulse inhibition and increases in locomotor activity by competitive N-methyl-D-aspartate receptor antagonists in rats.
Bakshi VP; Tricklebank M; Neijt HC; Lehmann-Masten V; Geyer MA
J Pharmacol Exp Ther; 1999 Feb; 288(2):643-52. PubMed ID: 9918570
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of GlyT1 affect glycine transport via discrete binding sites.
Mezler M; Hornberger W; Mueller R; Schmidt M; Amberg W; Braje W; Ochse M; Schoemaker H; Behl B
Mol Pharmacol; 2008 Dec; 74(6):1705-15. PubMed ID: 18815213
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of fear extinction by infusion of glycine transporter blockers into the amygdala.
Mao SC; Lin HC; Gean PW
Mol Pharmacol; 2009 Aug; 76(2):369-78. PubMed ID: 19411609
[TBL] [Abstract][Full Text] [Related]
14. Neonatal NMDA receptor antagonist treatments have no effects on prepulse inhibition of postnatal day 25 Sprague-Dawley rats.
Boctor SY; Ferguson SA
Neurotoxicology; 2009 Jan; 30(1):151-4. PubMed ID: 19038286
[TBL] [Abstract][Full Text] [Related]
15. Effect of CFMTI, an allosteric metabotropic glutamate receptor 1 antagonist with antipsychotic activity, on Fos expression in regions of the brain related to schizophrenia.
Suzuki G; Satow A; Ohta H
Neuroscience; 2010 Jul; 168(3):787-96. PubMed ID: 20399255
[TBL] [Abstract][Full Text] [Related]
16. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one.
Satow A; Suzuki G; Maehara S; Hikichi H; Murai T; Murai T; Kawagoe-Takaki H; Hata M; Ito S; Ozaki S; Kawamoto H; Ohta H
J Pharmacol Exp Ther; 2009 Jul; 330(1):179-90. PubMed ID: 19359526
[TBL] [Abstract][Full Text] [Related]
17. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas.
Perry KW; Falcone JF; Fell MJ; Ryder JW; Yu H; Love PL; Katner J; Gordon KD; Wade MR; Man T; Nomikos GG; Phebus LA; Cauvin AJ; Johnson KW; Jones CK; Hoffmann BJ; Sandusky GE; Walter MW; Porter WJ; Yang L; Merchant KM; Shannon HE; Svensson KA
Neuropharmacology; 2008 Oct; 55(5):743-54. PubMed ID: 18602930
[TBL] [Abstract][Full Text] [Related]
18. Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine.
Hudson MR; Rind G; O'Brien TJ; Jones NC
Transl Psychiatry; 2016 Apr; 6(4):e784. PubMed ID: 27093066
[TBL] [Abstract][Full Text] [Related]
19. Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity.
Galici R; Boggs JD; Miller KL; Bonaventure P; Atack JR
Behav Pharmacol; 2008 Mar; 19(2):153-9. PubMed ID: 18332680
[TBL] [Abstract][Full Text] [Related]
20. Design of potent GlyT1 inhibitors: in vitro and in vivo profiles.
Bridges TM; Williams R; Lindsley CW
Curr Opin Mol Ther; 2008 Dec; 10(6):591-601. PubMed ID: 19051137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
